New UPSC Foundation, Optional and TGPSC/APPSC batches are open — book your counselling slot.Explore coursesGroup 2 crash course ₹9,999Today's Current AffairsToday's Daily QuizPlaces in NewsCall 98804 87071

Economic Survey 2026 · Chapter 4 · Topic 8 of 18

India’s Pharmaceutical Transformation After TRIPS

From process patents to innovation-led exports

Case study

Quick answer

Economic Survey 2025-26 traces pharmaceutical exports from US$1.9 billion in FY01 to US$30.5 billion in FY25, linking resilience to R&D and regulatory capability.

India’s pharmaceutical transformation after TRIPS was a shift from process-based imitation towards regulated-market generics, research and global partnerships. Box IV.1 uses this experience to explain how firms can respond to external restrictions through capability creation rather than permanent protection.

Chronology caution: WTO/TRIPS began in 1995; India introduced pharmaceutical product-patent protection in 2005 after its transition period. The box’s opening compresses these dates; its footnote identifies the 2005 amendment.

Concept diagram

India’s Pharmaceutical Transformation After TRIPS

India’s pharmaceutical transformation combines manufacturing capability with patent compliance, quality assurance and innovation.

  • TRIPS changed the patent environment
  • Innovation complements generic-drug capability

Process protection versus product protection

Process patent

  • Protects a manufacturing method, not necessarily the resulting molecule.
  • Under India’s earlier pharmaceutical regime, an alternative lawful process could enable production of the same drug.

Product patent

  • Protects the patented product; merely changing the process does not avoid product-patent rights.
  • TRIPS provides a minimum patent term of 20 years from filing, subject to patentability and permitted flexibilities.
VS

TRIPS requires protection for both products and processes in covered fields; product patents did not abolish process patents.

Data chart

Pharmaceutical export expansion across the adjustment

010203040US$ billionFY01FY25Pharmaceutical exports, FY01: 1.91.9Pharmaceutical exports, FY25: 30.530.5
  • Exports expanded nearly sixteenfold across these endpoints.
  • This long interval captures several changes; it is not a causal estimate of TRIPS alone.

Source: Economic Survey 2025-26, Box IV.1 (Department of Pharmaceuticals; Department of Commerce)

Show the data (US$ billion)
Period / itemPharmaceutical exports
FY011.9
FY2530.5

Scientific and regulatory capability deepened

IndicatorEarlier observationLater observation
Industry R&D expenditure₹1.25 billion, FY94Nearly ₹209.8 billion, FY19
India’s share of global Drug Master File filings14.5%, CY200048.7%, CY2007
Pharmaceutical exportsUS$1.9 billion, FY01US$30.5 billion, FY25

Four adaptations from the pharma playbook

  1. Upgrade science

    Develop formulation expertise, complex generics, novel delivery systems and new chemical entities.

  2. Build regulatory credibility

    Drug Master Files support technical documentation; ANDAs seek approval for generic drugs in the US.

  3. Share research risk

    Out-licensing, co-development and contract research/manufacturing spread financing and technical risk.

  4. Secure market presence

    Targeted overseas acquisitions can add distribution networks, local knowledge and compliance capacity.

Innovation with affordable access

Generics remain a legitimate business

  • Off-patent products and appropriately licensed products remain opportunities; TRIPS did not prohibit all generic medicines.
  • Regulatory approval concerns quality, safety and efficacy; patent permission is a separate legal question.

Transferable industrial lesson

  • A predictable research ecosystem, skilled scientists and credible regulators support competitiveness under stricter global rules.
  • Public policy should balance incentives to innovate with affordability and lawful access safeguards; not every smaller firm can absorb compliance costs equally.

Patent chronology and approval traps

Statements examiners like to twist — learn the correct version.

  • India’s pharmaceutical product patents started with WTO membership in 1995.

    1995 began WTO/TRIPS obligations; the pharmaceutical product-patent transition culminated in the 2005 amendment.

  • A Drug Master File is a patent or automatic drug approval.

    A DMF supplies confidential technical information supporting regulatory review; it does not itself confer patent rights or marketing approval.

  • The endpoint export increase proves patents alone caused growth.

    R&D, global demand, regulatory access, partnerships and market diversification also shaped the outcome.

Prelims focus

  • TRIPS: WTO agreement; minimum patent term of 20 years from filing.
  • Distinguish APIs, generics, DMFs and ANDAs; keep the 1995/2005 timeline clear.

Mains angle

  • Use Box IV.1 to discuss whether external shocks can catalyse industrial upgrading.
  • Evaluate innovation incentives alongside affordable medicines and the needs of smaller manufacturers.

Flip & recall

Answer in your head first, then tap the card to check.

Practice MCQs

Original Prelims-style questions with explanations.

0 / 3 correct · 3 left

  1. Q1.India’s pharmaceutical product-patent transition culminated in which year?

  2. Q2.Which best describes an ANDA?

  3. Q3.Which inference best matches Box IV.1?

Free UPSC daily current affairs quiz — 10 questions, new every day at 8 am IST.

Call nowWhatsApp